Skip to content

DeepLife vs Envisagenics

DeepLife logo

DeepLife

AI for digital twin of cells

29 employees · est. 2019 · Paris, France

VS
Envisagenics logo

Envisagenics

Artificial Intelligence, High Performance Computing, and RNA sequencing data to find cures faster than ever before

36 employees · est. 2014 · New York, United States

Envisagenics is the older company (2019 vs 2014).

Side-by-Side Comparison

DeepLife Envisagenics
Founded
2019 2014 older
Headquarters
Paris, France New York, United States
Employees
29 36
Industry
AI, Biotechnology, Machine Learning AI, Biotechnology, Health and Wellness
Funding Stage
Series A Series B
Total Funding
$16.00M $33.38M
Funding Rounds
3 15
Services
Development of digital twins for cells, Drug discovery solutions, Multi-omics data analysis, AI and systems engineering for biotech applications AI-powered drug discovery, RNA splicing analysis, Therapeutic target identification, Biomedical research collaboration
Target Customers
Pharmaceutical companies, Biotech researchers, Health institutions, Investors interested in biotech innovations, Scientific collaborators Biopharmaceutical companies, Cancer researchers, Neurodegenerative disease researchers, Healthcare organizations
Taxonomy
Digital TwinCell EngineeringSaaS PlatformMulti-omics SequencingDeep Learning AlgorithmsIn Silico Simulations +8 High Performance ComputingRNA SequencingRNA SplicingDrug DiscoveryGenetic DiseasesCancer Research +8
Website
deeplife.co envisagenics.com
DeepLife logo

About DeepLife

DeepLife, an innovative startup founded in 2019, is making significant strides in biotechnology by developing the first SaaS platform for creating a Digital Twin of cells. They leverage advanced AI and machine learning to transform cell engineering by simulating cell behavior in silico, aiming to co...

Envisagenics logo

About Envisagenics

Envisagenics is a pioneering biotech company established in 2014 as a spinout of Cold Spring Harbor Laboratory. With a mission to simplify biomedical data and expedite therapeutic development, Envisagenics employs cutting-edge Artificial Intelligence and RNA sequencing analytics. Their focus on RNA...

Also comparing in this category

Comparing more than these two?

Get DeepLife, Envisagenics and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does DeepLife compare?

A PDF of DeepLife and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

DeepLife was founded in 2019, based in Paris, France, with 29 employees. DeepLife, an innovative startup founded in 2019, is making significant strides in biotechnology by developing the first SaaS platform for creating a Digital Twin of cells. They leverage advanced AI an. Envisagenics was founded in 2014, based in New York, United States, with 36 employees. Envisagenics is a pioneering biotech company established in 2014 as a spinout of Cold Spring Harbor Laboratory. With a mission to simplify biomedical data and expedite therapeutic development, Envisag.
DeepLife has raised $16.00M and Envisagenics $33.38M. Latest stage: DeepLife Series A, Envisagenics Series B.
Both work in AI, Biotechnology and Machine Learning and list drug discovery among their focus areas.

Compare DeepLife with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at DeepLife on 15 Jun 2026, and Envisagenics on 2 Apr 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout